Our Company was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name `Rubicon Consultants Private Limited', pursuant to a certificate of incorporation issued by the RoC. Subsequently, pursuant to a resolution passed by our Board and by our Shareholders on May 6, 2022 and June 15, 2002, respectively, the name of our Company was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' as we had set-up a pharma research laboratory, entered into contracts with customers from the pharma industry and was in the process of making applications to secretary, Department of Scientific and Industrial Research, Ministry of Science and Technology for carrying on scientific research development in our laboratories, consequent to which a fresh certificate of incorporation was issued by the RoC dated September 2, 2002 under the Companies Act, 1956. Furthermore, our Company's status was converted from a private limited company to a public limited company pursuant to a resolution passed by our Board and by our Shareholders on April 11, 2024 and May 13, 2024, respectively, the name of our Company was changed from `Rubicon Research Private Limited' to `Rubicon Research Limited' under Companies Act, 2013. A fresh certificate of incorporation dated July 23, 2024 was issued by the registrar of companies, central processing centre, Manesar, Haryana consequent to our Company's conversion into a public limited company.Major Events and Milestones:2007- Received investment from Kotak India Venture Fund - I, Kotak India Venture Limited and Kotak Employees Investment Trust.2011- Commencement of manufacturing of certain special drugs in Ambernath Manufacturing Facility.- Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility for tablet manufacturing and secondary packaging by Medicines and Healthcare Products Regulatory Agency, United Kingdom.2013- Receipt of GMP clearance approval for Ambernath Manufacturing Facility from Department of Health and Ageing Therapeutic Goods Administration, Australian Government.2014- Receipt of approval for our product i.e., `metoprolol tartrate tablets' from the Food & Drug Administration, United State of America.2016- Acquisition of majority stake by ECP III Pte Ltd.2017- Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility from the Ministerio De Sandidad, Servicios Sociales E Igualdad, Spain.2019- Acquisition of majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd.- Acquisition of Impopharma Canada Limited by Rubicon Research Canada Limited2021- Acquired the business of Meditab Specialities Limited on a slump sale basis.2022- Set up own sales and marketing front end in US via our Material Subsidiary2023- Receipt of certificate of GMP compliance for Satara Manufacturing Facility of non-sterile liquid drug manufacturer and pre-approval coverage provided for non-sterile liquid product by US FDA2024- Acquisition of Validus Pharmaceuticals LLC.- ANDA pre-approval drug inspection of nasal spray block at Ambernath Manufacturing Facility by USFDA.- Receipt of supplement approval for Thane R&D Facility as a testing site of drug substance - lead test from USFDA.- Received USFDA establishment inspection report for Ambernath Manufacturing Facility.- Commencement of manufacturing of nasal products at Ambernath Manufacturing Facility.2025- Received new drug application approval from USFDA for Lopressor (Metoprolol Tartrate) oral solution.- Received USFDA establishment inspection report for Thane R&D Facility.- Acquisition of Pithampur Manufacturing Facility from Alkem Laboratories Limited.- Acquisition of AIM RX 3PL LLC.